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ABSTRACT 
EVALUATION OF BERRY EXTRACTS ON INTESTINAL DIGESTIVE 
ENZMYES AND SUGAR TRNASPORTERS 
MAY 2017 
JUNGBAE OH, B.S, UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S, UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: DR. Young-Cheul Kim 
 
Diabetes mellitus affects over 8% of the world population, with the great majority 
having type 2 diabetes mellitus (T2DM). T2DM is characterized by postprandial 
hyperglycemia and has been identified as key causes of morbidity and mortality with 
substantial health care costs due to its complications. Therefore, managing postprandial 
hyperglycemia can be an important and practical approach to reduce premature 
morbidity and mortality and economic loss. The causes of T2DM are multifactorial and 
include both genetic and environmental factors. Also, increased oxidative stress can be 
influenced on the prevalence of T2DM. However, sedentary lifestyle and high-calorie 
diets are considered as major contributing factors for the development of T2DM. In 
particular, consumption of high sucrose elevates blood glucose level dramatically. Thus, 
artificial sweeteners were extensively used, however artificial sweeteners are also 
increased the prevalence of T2DM. One of the therapeutic approaches to attenuate 
hyperglycemia is to inhibit intestinal ɑ- glucosidase enzyme and suppress glucose 
transporters that regulate intestinal glucose digestion and absorption. In recent studies, 
consumption of fruits and vegetables has been shown to decrease postprandial 
v 
hyperglycemia and risk of T2DM by inhibiting carbohydrate digestion and absorption 
in the small intestine due to their bioactive compounds. Therefore, there is an increased 
interest to find the natural sources to prevent T2DM. In particular, demands of berry 
fruits are increased steadily due their natural antioxidants and bioactive compounds. 
The antidiabetic effects of various berry extracts or berry mixture in pre-clinical and 
clinical studies were shown. However, the underlying pathways of individual berries at 
the molecular level are still unclear. Also, it has not been investigated whether berries 
can manage the plasma glucose with dietary factors. It may be possible that beneficial 
effects of berry consumption could be through inhibiting carbohydrate digestion and 
absorption in the small intestine and it can be applied to dietary strategy so that 
postprandial hyperglycemia can be managed effectively. 
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CHAPTER 1 
INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder and one of the major global 
health problems in the modern era [1]. According to CDC reports, 8.3% of the 
population already had diabetes in 2010 [2], and people with T2DM have about 2 to 4 
times higher risk of other complications such as cardiovascular disease (CVD) or stroke 
in the United States [3]. A high caloric intake as a high-sugar and high-fat diet combined 
with a sedentary lifestyle has been identified as primary determinants in the 
development of obesity and T2DM [4]. In particular, a dramatic increase in the 
prevalence of obesity and T2DM has also been strongly correlated with sugar-
sweetened beverages consumption in different population groups [5-8]. In recent years, 
non-calorie and non-digestible artificial sweetener (AS), sucralose, have been 
extensively used in a variety of food products as an alternative to simple sugars [9]. 
However, emerging evidence suggest that consumption of AS-contained beverages also 
increase the risk of T2DM and metabolic disorders [10, 11], which may be partially 
through upregulation of glucose absorption in the small intestine [12]. Although the 
global epidemic of obesity mostly explains the increased incidence and prevalence of 
T2DM, the precise mechanisms linking obesity to T2DM still remain unclear.  
Among the characteristics, postprandial hyperglycemia is a hallmark of T2DM that has 
been recognized as an early defect in diabetic patients and prediabetic individuals [13]. 
Postprandial hyperglycemia can be caused by decreased glucose utilization in 
peripheral tissues, resulting in insulin resistance [14]. It can also result from increased 
rate of intestinal digestion and absorption from dietary carbohydrates [15]. Therefore, 
identifying dietary bioactive components that can delay carbohydrate digestion and 
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absorption in the small intestine to prevent postprandial hyperglycemia is crucial for 
the management of T2DM [16]. 
One of the primary targets of antidiabetic drugs such as acarbose is to inhibit intestinal 
carbohydrate digesting enzymes and sugar transport proteins, which have been 
demonstrated to be effective in reducing hyperglycemia after a meal [17]. However, 
these anti-diabetic drugs are often reported to cause several side effects such as nausea, 
vomiting, abdominal cramps [18] or urinary tract infections [19]. Therefore, there has 
been increasing interest in investigating dietary bioactive constituents from natural 
sources that may modulate carbohydrate digestion and absorption in the small intestine.  
Among natural sources, fruits and vegetables have many beneficial nutrients and 
phytochemicals that are thought to protect against T2DM [20, 21]. In particular, 
demands of cranberries among consumers have been increased due to valuable 
bioactive compounds [22] that reduce the risk of CVD [23, 24] and urinary tract 
infection [25]. Recent research has also shown an anti-diabetic potential of cranberries 
in both clinical studies [26] and in vivo animal studies [27]. Antidiabetic properties of 
cranberry consumption may result from delayed digestion and absorption of 
carbohydrates in the small intestine. Several in vitro studies reported that cranberry 
extracts and its bioactive compounds inhibit yeast ɑ-glucosidase activity [28] as well 
as rat ɑ-glucosidase activity [29]. In addition, berry mixtures prepared from several 
berries including cranberries have also shown decreased glucose uptake by inhibiting 
glucose transporters in Caco-2 intestinal cells [30].  
Among many different types of berries, blackberry extracts have been reported to have 
hypoglycemic effects in animal studies [31, 32] and in vitro studies, where blackberries 
inhibited yeast ɑ-glucosidase activity [33]. However, postprandial anti-hypoglycemic 
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effects of blackberries have not been studied in in vivo settings.  
Dietary polyphenols have received immense attention among nutritionists, researchers, 
and consumers due mainly to their important roles in human health such as disease 
prevention and health promotion. Among the wide range of polyphenols, the most 
abundant polyphenols present in berries are anthocyanidins, proanthocyanidins, 
flavanols, and phenolic acids [34]. Those biological substances in berries have been 
demonstrated to have health benefits in humans with strong antioxidant and anti-
inflammatory activities [35-37]. Furthermore, recent research has shown an antidiabetic 
potential of dietary berry polyphenols by inhibiting glucose uptake in human Caco-2 
intestinal cells [30, 38]. This may indicate that quantity as well as compositions of berry 
polyphenols is important to achieve health benefits. While there is some evidence from 
the published studies that cranberries and blackberries or their bioactive compounds 
inhibit both yeast and rat ɑ-glucosidase enzyme activity, it is currently unclear whether 
cranberries and blackberries exert inhibitory effects on ɑ-glucosidase activity in human 
cell models of intestinal absorptive function such as Caco-2 intestinal cells. Moreover, 
the underlying molecular mechanisms of individual berries on intestinal carbohydrate 
digestion and absorption are not well understood. Although several studies have 
evaluated the antidiabetic potential of various berries, dietary conditions such as in the 
presence of dietary carbohydrates and AS were not considered. Therefore, it is not 
known whether cranberries and blackberries may suppress intestinal digestion and 
absorption of carbohydrates in the presence of various dietary carbohydrate sources.   
The overall goal of this study was to identify potential role of berries as part of a dietary 
strategy and molecular mechanisms so that postprandial hyperglycemia can be 
managed effectively and the need for pharmacotherapy could be greatly reduced. The 
aims of the study were (1) to determine the extent to which cranberry extracts (CBE) 
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and blackberry extracts (BBE) regulate intestinal ɑ-glucosidase and/or gene expression 
of glucose transporters; (2) whether this correlates with the level of glucose uptake 
using human Caco-2 intestinal cells; and (3) investigate whether CBE and BBE 
modulate intestinal ɑ-glucosidase and glucose transporters in the presence of dietary 
carbohydrates and AS. 
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CHAPTER 2 
 LITERATURE REVIEW 
2.1 Trends of type 2 diabetes (T2DM): Global epidemic  
T2DM is a metabolic disorder of fat and glucose metabolism and is the most common 
form of diabetes [1]. The estimated worldwide prevalence of T2DM has continued to 
increase dramatically during the past two decades [39]. According to World Health 
Organization (WHO), the prevalence of diabetes in adult population worldwide is 8.5% 
in 2014 and is about two times higher compared to1980 [40]. In addition, it is estimated 
that over 360 million people would have T2DM by the year 2030 [41]. 
The rising prevalence of T2DM is especially notable in low and middle-income 
countries [42]. For example, the prevalence of T2DM in developing countries in Asia 
has increased three to five folds during the past 30 years and now accounts for about 
60% of the global diabetic population. As this trends will continue to increase at this 
rate, this will certainly be a major global health issue [43]. While the rise of T2DM has 
been mostly observed in the adult population, increasing prevalence of T2DM in youth 
will become a serious new T2DM epidemic in the 21st century [44]. Until 1990, the 
prevalence of T2DM was rarely seen in childhood. However, the T2DM prevalence rate 
in youth has been significantly increased within ten years in many other countries [45]. 
Such dramatic increases of T2DM in low and middle-income class and young ages are 
strongly linked to changes in lifestyles with high-calorie diets such as high 
carbohydrates and high fat [4].  
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2.1.1 Diabetic complications & economic burden 
Diabetes and its complications affect many different organ systems in the body over a 
period of time and are a major cause of morbidity and mortality with substantial health 
care costs [3]. According to National Health and Nutrition Examination Survey 
(NHANES), chronic kidney disease showed the highest prevalence rates (27.8 %), 
followed by foot problems (22. 9%) and eye damages (18. 9%), which are classified as 
a microvascular disease. While the prevalence rate of microvascular accounts for 
around 70%, the mortality rate of diabetic complications is mainly due to macrovascular 
disease such as heart disease and stroke, which accounts for 9.8% and 6.6%, 
respectively [46].  
The burden of diabetes is not only on the health, but also on total health care cost. 
According to the American Diabetes Association (ADA), direct and indirect health care 
costs for diabetes is estimated over 240 billion dollars in 2012 [47]. Notably, 
approximately 40% of the total cost of diabetes is due to treatment of diabetes 
complications, and it is estimated that diabetes-related macrovascular disease 
accounted for 85% of cumulative costs of diabetic complications [48].  
Among the risk factors, hyperglycemia has been identified as a key diagnostic measure 
of T2DM and also as major diabetes-mediated health complications. [49, 50]. Thus, 
improvement of postprandial hyperglycemia has been effective in attenuating the 
macrovascular complications in diabetic patients [51-53]. As a consequence, managing 
postprandial hyperglycemia can be an important and practical approach to reduce 
premature morbidity and mortality as well as economic burdens.  
 
 
7 
2.2 Pathophysiology of T2DM  
The causes of T2DM are multifactorial and include both genetic and environmental 
factors that ß-cell function and insulin sensitivity in peripheral tissue [54]. Even though 
the numbers of genomes are associated with the prevalence of T2DM, a relatively small 
percentage is due to monogenic causes [55]. Epidemiological and experimental 
evidence supported that environmental factors including obesity, sedentary lifestyle, 
and high-calorie diets are major contributing factors for the development of T2DM [56-
58]. Notably, high carbohydrates and high fat diets have been shown to induce T2DM 
by a combination of pancreatic ß-cell dysfunction and insulin resistance in peripheral 
tissues [56].  
Under normal physiological conditions, postprandial plasma glucose concentrations are 
regulated by the actions of hormones, mainly insulin and glucagon [59]. In the fed state, 
pancreatic islet ß-cells secrete insulin in response to plasma glucose level. As a 
consequence of insulin secretion, plasma glucose is transported into insulin-sensitive 
peripheral tissues via glucose transporters and anabolic metabolism is promoted. 
Furthermore, glucagon secretion is inhibited so that lipolysis in adipose tissue and 
hepatic gluconeogenesis are suppressed [56].  
On the other hand, diets high in carbohydrates and fat cause substantial hyperglycemia, 
resulting in increased peripheral tissues insulin resistance and islet ß-cells dysfunction 
[60, 61]. In addition, the insulin resistance state is an impairment in the insulin-
mediated suppression of lipolysis and increased secretion of pro-inflammatory 
cytokines in adipose tissue, which in turn aggravate insulin resistance in muscle and 
liver. [62]. Numerous studies have demonstrated that elevated plasma free fatty acids 
(FFAs) as a result of increased adipose lipolysis impair insulin-stimulated glucose 
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uptake in skeletal muscle. Similarly, elevated FFAs also stimulate hepatic 
gluconeogenesis, and endogenous glucose production, which results in decreased 
hepatic insulin action with increase the severity of insulin resistance [63].  
While reduced glucose utilization by peripheral tissues in insulin resistant state elevates 
plasma glucose level, postprandial hyperglycemia can also be directed affected by types 
and composition of dietary carbohydrates as well as their intestinal digestion [16]. One 
important therapeutic approaches for treating postprandial high blood glucose in T2DM 
is to reduce digestion and absorption of dietary carbohydrates. These approaches can 
be accomplished by inhibiting carbohydrate hydrolyzing enzymes in the small intestine. 
In humans, ɑ-1-4 glycosidic linkage of complex carbohydrates is digested into 
disaccharides and oligosaccharides by the action of salivary and pancreatic ɑ-amylase. 
Then, disaccharides are further hydrolyzed into monosaccharides by the action of two 
subunits of ɑ-glucosidiase, sucrase-isomaltase (S-I) and maltase-glucoamylase (M-G), 
in the apical membrane of the small intestine [64].  
Absorption of monosaccharides involved transport from the intestinal lumen into 
epithelial cells. The glucose and galactose are carried by the sodium-dependent glucose 
transporters 1 (SGLT1), while fructose is carried by the glucose transporter 5 (GLUT5). 
Glucose, galactose, and fructose are then transported out of the enterocyte via another 
hexose transporter, glucose transporter 2 (GLUT2) across basolateral membrane and 
into blood [65]. Recent in vivo animal studies suggested that GLUT2 can also be 
recruited into the apical side of membrane when the luminal glucose concentration is 
high such as occurs in the fed state, enhancing facilitated diffusion [65]. Thus, 
retardation of intestinal glucose absorption by inhibiting intestinal glucose transporters 
has been targeted to reduce postprandial hyperglycemia.  
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2.3 Role of oxidative stress & antioxidant in metabolic disorders & diabetes  
Free radicals are reactive atoms that have one or more unpaired electrons that are 
associated with many cellular process and human disease, depending on concentration. 
[66]. In the human body, oxidants or reactive oxygen species (ROS) including hydroxyl 
(OH•), superoxide (O2•–) are generated as a consequence of a variety of normal 
physiological metabolism and particularly, cellular oxidative phosphorylation in the 
mitochondria [67, 68]. At low concentrations, oxidants or ROS during normal 
physiological processes, it acts as stimuli for cell signaling, however, excessive of ROS 
or oxidants can react with lipids, proteins, and nucleic acids, causing cellular damages 
or apoptosis, and even diabetes and other metabolic complications [67].  
Free radicals produced from normal physiological metabolisms are effectively 
neutralized by non-enzymatic and enzymatic antioxidants to prevent the propagation of 
free radical reactions or oxidants, maintaining the balance of redox system [69]. The 
endogenous antioxidant enzymes include superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GPx) and glutathione reductase (GR). SOD is located in the 
cytosol (Cu,Zu-SOD) and mitochondria (Mn-SOD) and converts superoxide anion 
radicals into oxygen and less toxic hydrogen peroxide [70]. The enzyme Cat present in 
the peroxisomes further decomposes hydrogen peroxide into oxygen and water. In 
addition, the enzyme GPx degrades both hydrogen peroxide and lipid hydroxy 
peroxides in coordination with glutathione reductase in the presence of NADPH as a 
cofactor [71].  
Recent studies suggest that postprandial hyperglycemia causes overproduction of 
superoxide anions via mitochondrial electron transport chain which exceeds 
endogenous antioxidant capacity and shift into oxidative stress [49]. Endogenous 
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defense system becomes weakened and unable to counteract the increased ROS, 
causing tissue damage through multiple mechanisms. Cellular injury by ROS from 
hyperglycemia involves enhanced polyol pathway and increased cellular formation of 
advanced glycation end products (AGEs), which are known to activate protein kinase 
(PKC) and NF-kB, key mediators of islet ß-cell dysfunction [72]. Therefore, 
consumption of exogenous antioxidants has been emphasized to maintain the oxidant-
antioxidant balance in our body. 
 
2.4 Oral anti-hyperglycemic therapies for Type 2 diabetes   
Diet modification with regular physical activities is recommended for preventing the 
prevalence of T2DM and is central concepts of any therapeutic programs. Emerging 
studies suggested that a significant reduction in the incidence of T2DM through 
lifestyle and diet modifications [58, 73]. Because of elevated fasting and postprandial 
blood glucose that expose patients to acute and chronic health complications, 
pharmacological therapies are mainly targeting glycemic control by the drugs that 
increase glucose utilization in peripheral tissues or suppress digestion and absorption 
of dietary carbohydrates in the small intestine [74]. Some of the available 
pharmacological agents include Sulfonylureas, Biguanides, Thiazolidinedione, 
intestinal ɑ-glucosidase inhibitors, and intestinal glucose transporter inhibitors as 
discussed below. 
2.4.1 Sulfonylureas 
Sulfonylureas are the oldest antidiabetic agents and are commonly prescribed for the 
treatment of T2DM patients [75]. The most significant effect of sulfonylureas is to 
suppress glucagon secretion from pancreatic α-cells and increase plasma levels of 
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insulin secreted from pancreatic β-cells, even though extra pancreatic actions may also 
contribute to their anti-hyperglycemia effects [76]. Thereby, treatment with 
sulfonylureas decreases plasma glucose and HbA1c level [74]. However, stimulation 
of endogenous insulin secretion via sulfonylureas often causes loss of efficacy over 
time, which appears to be related to exhaustion of ß-cell function. Hypoglycemia and 
weight gain are the two frequently observed side effects of these drugs. In particular, 
elderly T2DM patients have over 30% increased the risk of hypoglycemia than younger 
patients so that sulfonylureas therapy should be carefully monitored avoided in elder 
people with diabetes [77].  
2.4.2 Biguanides 
Metformin is one of the biguanides that commonly prescribed for T2DM treatment for 
long period of time [78]. The precise mode of action of metformin is not fully 
understood, but predominant effects of metformin are to suppresses hepatic glucose 
production through inhibition of gluconeogenesis [79]. Also, metformin acts as an 
insulin-sensitizer that stimulates glucose uptake in peripheral tissues such as skeletal 
muscle [80] and decreases the absorption of glucose from the gastrointestinal track. 
Therefore, metformin reduces postprandial hyperglycemia without promoting weight 
gain. [81]. Side effects associated with metformin therapy are gastrointestinal 
complaints and lactic acidosis [82] so that care should be taken from those affected 
individuals.  
2.4.3 Thiazolidinedione (TZD) 
TZDs is one of the oral antidiabetic drugs that improves glycemic control in T2DM 
patients through the improvement of insulin sensitivity in peripheral tissues [83]. TZDs 
are synthetic ligands for a nuclear receptor, peroxisome-proliferator-activated receptor 
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gamma (PPARγ), and the most prominent effect of TZDs is thus mediated by PPARγ 
through stimulation of glucose into skeletal muscle and adipose tissue, a process which 
requires insulin [84]. The major side effects of TZDs are primarily associated with 
weight gain and edema. In some cases, TZDs are reported to increase the risk of heart 
failure in patients with T2DM [85]. Because of these reported adverse events, the 
therapy needs to be prescribed with caution and more studies are in needed for its safety. 
2.4.4 Intestinal ɑ-glucosidase inhibitors (AGIs) 
Acarbose, Voglibose, and Miglitol are ɑ-glucosidase inhibitors (AGI) that have been 
prescribed for managing postprandial glucose level in pre-diabetic and diabetic patients 
[86]. AGIs act as competitive and reversible inhibitors of the ɑ-glucosidase enzyme, 
which delay intestinal digestion and absorption of carbohydrates and mitigate rapid 
spike of plasma glucose level after a meal [87]. AGIs are considered to be safe and 
effective because it is rarely absorbed in our body. Due to AGIs regulation of 
postprandial hyperglycemia, AGIs have been shown a significant reduction in the risk 
of CVD and hypertension in clinical studies [88]. Moreover, unlike sulfonylureas, AGIs 
do not affect plasma insulin levels. As a result, they do not cause hypoglycemia when 
used alone. These agents are not usually used for primary therapy and most useful in 
combination with other drugs. Gastrointestinal side effects are common and the major 
complaints are bloating, flatulence, diarrhea, abdominal discomfort, and pain [18].  
2.4.5 Intestinal glucose transporter inhibitors  
SGLT1 is essential for intestinal glucose and galactose absorption and inhibitors such 
as sotagliflozin (LX4211) have been reported to hold promise in improving glycemic 
control by retarding postprandial glucose peaks in T2DM [19]. The efficacy of 
sotagliflozin has been encouraging as it effectively reduces blood HbA1c and glucose 
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levels, suggesting potential efficacy in T2DM [89]. In particular, a dual inhibitory 
action of sotagliflozin on intestinal SGLT1 and SLGT2 would provide unique insulin-
independent mechanisms to treat T2DM [89]. Hypoglycemia and urinary track 
infections are notable side effects due to increased delivery of sugars to the distal region 
of the small intestine and colon [19]. While promising from a clinical profile of 
postprandial plasma glucose reduction, longer term studies with larger sample sizes are 
needed to fully characterize the efficiacy and safety of the drugs. 
 
2.5 Role of diet & dietary components in diabetes  
Recent epidemiological studies suggested that dramatic increases in obesity and T2DM 
have been observed in different population groups where consumed high fat and 
carbohydrate diets including sugar-sweetened beverage [5-8]. Thus, reducing 
carbohydrate and fat-rich meal have been shown to reduce postprandial glucose 
response in individuals with T2DM [57, 90, 91].  
Artificial sweeteners (ASs) are considered safe and beneficial owing to their non-
caloric and non-digestible characteristics. Therefore, AS has been extensively used in 
variety food products as an alternative to sugars [9]. Although the impact of ASs on 
metabolic diseases is controversial, recent evidence clearly suggested that consumption 
of ASs especially artificially sweetened beverages increased the risk of T2DM and 
metabolic disorders [10, 11, 92, 93]. The molecular mechanisms of AS on metabolic 
disorder and T2DM are yet to be investigated. However, it has been reported that ASs 
increase postprandial hyperglycemia by increasing intestinal glucose transporters [12].  
For individuals with T2DM, a recommended diet high in fruits, vegetables, and dietary 
fiber has proven beneficial in lowering markers related to oxidative stress as well as in 
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managing postprandial hyperglycemia. Fruits and vegetables are primary dietary 
sources many essential nutrients and phytochemicals that are recognized to prevent or 
delay the risk of T2DM [20, 21]. A variety of phenolic compounds including the family 
of flavonoids, flavanols, flavanones, flavones, and anthocyanidins are also found in the 
fruits and vegetables [94], which are also abundant source of vitamins and minerals 
[95]. The antioxidant properties of fruits and vegetables are due to a chemical structure 
of phenolic compounds and aromatic phenolic rings that are able to donate hydrogens 
to stabilize free radicals [96]. In addition, phytochemicals in fruits and vegetables have 
been shown to inhibit intestinal ɑ-glucosidase activity[97], delaying carbohydrate 
digestion and absorption into body [98]. Therefore, primary dietary intervention 
strategies employ increased consumption of fruits and vegetable rich in dietary fibers. 
 
2.6 Berries and their roles in health & diabetes  
Berry fruits are a rich source of natural antioxidants and also high contents of bioactive 
compounds including ascorbic acid, anthocyanins, phenolic acids, flavanols, flavonols 
and tannins [99-101]. Due to high amounts of bioactive and health-promoting 
compounds, berries are widely recognized as functional products that provide health 
benefits beyond basic nutrition as well as prevent metabolic disorders. 
Several intervention studies have investigated the effects of different berries on CVD 
in healthy humans or people with CVD risk factor. Those studies suggested that berry 
fruits significantly decrease postprandial oxidative stress and low-density lipoprotein 
oxidation, suggesting that berry intake may prevent the incidence of CVD. [102-105]. 
Currently, the impacts on glucose metabolism have been limited although recent in vitro 
studies indicate potential effects of berry extracts at the level of the small intestine. 
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Recent evidence demonstrated that consumption of berries or berry mixture 
significantly reduced postprandial hyperglycemia in healthy individuals [106-109]. For 
example, bilberry extracts have been reported to ameliorate hyperglycemia and insulin 
sensitivity in T2Dm mice via activation of AMP-activated kinase (AMPK) [110]. In 
addition, various berry extracts and polyphenols derived from berries can inhibit starch 
digestive enzymes and glucose transporters in the gastrointestinal track in vitro [111]. 
Many studies so far have investigated the effects of bioactive polyphenols isolated from 
berries or berry mixture on starch digestive enzymes and glucose transporters. It is thus 
possible that beneficial effects of berry consumption could be through there and/or 
other cellular targets that may aid in reducing postprandial glucose levels and enhancing 
insulin sensitivity, which could support the use of berries or berry extracts to manage 
metabolic disorders. Further studies of the effect of berry consumption on gene 
expression are valuable to identify potential mechanisms of action.  
2.6.1 Cranberries  
The America cranberries (Vaccinium macrocarpon) is one of the berries commonly 
consumed in America, and over 90% of global cranberries are produced in global [112]. 
Cranberries have been known to be rich sources of phytochemicals. Currently, over 150 
individual phytochemicals including anthocyanins have been identified [113]. Several 
human studies provide evidence for effect of cranberry bioactive on chronic disease. In 
particular, cranberries are well known to reduce the risk of urinary tract infections [114, 
115] and CVD [23, 24] that led to the inclusion of cranberries to modifications. Also, 
clinical and animal studies from recent years have revealed new health benefits of 
cranberry consumption on T2DM prevention although effects of cranberries on 
postprandial hyperglycemia are currently limited. It has been shown that consumption 
of raw cranberries exhibits a favorable response to plasma insulin and glucose levels in 
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people with T2DM [26], and high fructose diet with cranberry powder for 11 weeks 
tend to reduce postprandial hyperglycemia in an animal model [27]. Antidiabetic 
properties of cranberries may result from delaying intestinal digestion and absorption 
of carbohydrates. There is an evidence showing that cranberries inhibit yeast ɑ-
glucosidase activity [28] and a bioactive compound in cranberries, Cyanidin-3-
galactoside, also suppresses rat ɑ-glucosidase activity [29]. In addition, in both short 
and long-term exposure of berry mixture, which derived from several berries including 
cranberries, decreased two main glucose transporters, SGLT1 and GLUT2, as well as 
glucose uptake in human Caco-2 intestinal cells [30]. While a body of evidence suggest 
that glucose absorption across the apical membrane of enterocyte is hindered by berry 
polyphenols, the precise contribution of specific bioactive compounds and individual 
berries has not been studied. These further studies will warrant identification of 
important modulators of the rate of glucose digestion and absorption and thus of plasma 
blood glucose levels. 
2.6.2 Blackberries  
Blackberry (Rubus sp.) is known to have high contents of phenolics including 
anthocyanins and ellagitannins, which contribute to potent antioxidant properties and 
other biological benefits of blackberries [116]. In vitro studies have shown that 
blackberry extracts exhort inhibitory effects of A549 human lung cancer with reduced 
neoplastic transformation in in normal epidermal mouse cells [117]. Furthermore, 
blackberry extracts have the dose-dependent anti-proliferate effects in various cancer 
cell lines including human oral, breast, prostate, and colon cancer cell line [117]. While 
anticarcinogenic properties of blackberries have been demonstrated in several in vitro 
studies, possible health benefits against such metabolic disorder like blood glucose 
regulation and T2DM have not been extensively studied. In particular, it has not been 
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studied in relation to postprandial hyperglycemia in a clinical study. However, limited 
evidence showed that dietary supplementation of blackberry extracts in rats for 80 days 
decreased plasma glucose concentration and increased peripheral tissue insulin 
sensitivity [31]. Also, blackberry intake significantly decreased fasting blood glucose 
level on diabetic rats [32]. These results indicate that hypoglycemic effects of 
blackberries may contribute to decreased the risk of T2DM and it may result from 
inhibition of intestinal ɑ-glucosidase activity, which was shown in vitro study [33]. 
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CHAPTER 3 
BERRY EXTRACT EXERT ANTI-DIABETIC EFFECTS VIA INHIBTION OF 
α-GLUCOSIDASE AND GLUCOSE TRANSPORTERS IN HUMAN 
INTESTINAL EPITHELIAL CACO-2 CELLS 
 
3.1 Abstract 
T2DM is a chronic disease characterized by postprandial hyperglycemia. One of the 
therapeutic approaches to attenuate hyperglycemia is to inhibit intestinal ɑ-glucosidase 
enzyme and/or suppress glucose transporters that regulate intestinal glucose 
transporters such as SGLT1 & GLUT2. Berries rich in polyphenol antioxidants have 
various health benefits. Although the antidiabetic effects of various berry extracts or 
berry mixture in pre-clinical and clinical studies, the underlying pathways at the 
molecular level is still unclear. In this study, we investigated antioxidant and 
antidiabetic effects of selected berry extracts by determining free radical scavenging 
activates, Caco-2 intestinal ɑ-glucosidase activity, glucose uptake and the gene 
expression of ɑ-glucosidase and glucose transporters in Caco-2 cells. Total phenolic 
contents of berry extracts varied from 28.55 ± 0.06 to 56.15 ± 1.08 gallic acid equivalent 
(GAE μg/mL) and correlated with antioxidant capacities. Both cranberry extract (CBE) 
and blackberry extract (BBE) at 200 μg/mL concentration significantly decreased 
glucose uptake in Caco-2 cells. While mRNA expression and activity of ɑ-glucosidase 
were inhibited by CBE and BBE, mRNA expression of SGLT1 and GLUT2 was only 
inhibited by CBE. Moreover, CBE and BBE significantly decreased glucose uptake in 
the presence of sucrose and AS. Our data suggest that CBE and BBE have different 
molecular mechanisms in suppressing hyperglycemia and their effects are mediated by 
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inhibiting carbohydrate digestion and absorption.  
 
3.2 Introduction 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by 
hyperglycemia and has been steadily increased during the past two decades worldwide 
[38]. Furthermore, people with T2DM have about 2 to 4 times higher risk of health 
complications such as cardiovascular disease (CVD), which is one of the major health 
problems in the 21st century [3]. Among the features of T2DM, postprandial 
hyperglycemia is a hallmark of clinical manifestations and a major contributor to 
metabolic complications [118]. Therefore, controlling postprandial hyperglycemia is 
recognized are prime clinical strategy for the prevention of T2DM and related 
cardiovascular events [119].  
As postprandial hyperglycemia is primarily regulated by the rate of intestinal digestion 
and absorption of carbohydrates [16], one of the therapeutic approaches for 
postprandial hyperglycemia is to retard intestinal digestion and absorption processes. 
In humans, complex dietary carbohydrates are digested into monosaccharides by the 
action of ɑ-amylase and ɑ-glucosidiases, mainly sucrase-isomaltase (S-I) and maltase-
glucoamylase (M-G), in the apical membrane of the small intestine [64]. Individual 
monosaccrides are then transported into enterocytes through glucose transporters, 
mainly sodium-dependent glucose transporter 1 (SGLT1) and non-sodium dependent 
glucose transporter 2 & 5 (GLUT2, GLUT5). Then, basolateral GLUT2 transports 
monosaccrides from enterocytes to the portal circulation [65]. Several epidemiological 
studies have shown a strong association between high carbohydrate diets and sugar-
sweetened beverages with hyperglycemia and T2DM [5-8]. Furthermore, non-digestive 
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and non-absorbable artificial sweeteners (AS), have been extensively used as 
alternatives to simple sugars that are shown to increase the risk of T2DM in clinical 
studies [10, 11]. A possible mechanism may involve upregulation of glucose absorption 
in the small intestine [12]. Therefore, diet modification with reduced consumption of 
dietary sugars or AS has been emphasized to help manage postprandial hyperglycemia.  
One of the pharmacological approaches to hyperglycemia and T2Dm is to modulate the 
intestinal digestion and absorption of dietary complex carbohydrates, decreasing 
postprandial blood glucose levels. There are several currently available drugs including 
agarose, an inhibitor of intestinal ɑ-glucosidase enzyme and sotagliflozin, an inhibitor 
of intestinal SGLT1. These drugs are designed to reduce glucose absorption in the GI 
track, and have been shown to be effective in reducing hyperglycemia after a meal [86, 
89]. However, these antidiabetic drugs often cause some side effects including 
flatulence, abnormal discomfort, diarrhea [18], and urinary tract infections [19]. 
Therefore, there have been increasing interests in finding dietary bioactive constituents 
from natural sources that can delay carbohydrate digestion and absorption in the small 
intestine without such adverse effects.  
It is well recognized that hyperglycemia induces overproduction of reactive oxygen 
species (ROS), which is known to cause both microvascular and macrovascular 
complication of diabetes [49]. Elevated oxidative stress also increases the formation of 
advanced glycation end-products (AGEs), causing islet ß-cell dysfunction via PKC and 
NF-kb pathways. [72]. Therefore, maintaining the balance between antioxidant and 
oxidant stress by dietary antioxidants is crucial to prevent hyperglycemia-mediated 
health complications.  
Phytochemicals that are thought to protect against postprandial hyperglycemia in 
21 
T2DM [20, 21] and one proposed mechanism is through retardation of glucose uptake 
at the small intestinal level [30, 38]. The consumption of berry fruits and their health 
benefits is a matter of considerable interest. In particular, cranberries have received 
much attention from the public due to many health benefits. Recent research has shown 
antidiabetic potential of cranberries in both human [26] and animals [27]. Several in 
vitro studies also reported that cranberry extracts or its bioactive compounds inhibit 
yeast ɑ-glucosidase activity [28] as well as rat ɑ-glucosidase activity [29]. In addition, 
berry mixture containing cranberries showed potency of retardation of glucose 
absorption of in Caco-2 intestinal cells [30]. Therefore, antidiabetic properties of 
cranberries may result from delayed digestion and absorption of carbohydrates in the 
small intestine. Among different types of berries, blackberries have been reported to 
have higher antioxidant capacity than cranberries [120] and exert hypoglycemic effects 
in animal studies [31, 32]. Using in vitro models, it was shown that blackberry cultivars 
inhibit ɑ-glucosidase activity, which may account for hypoglycemic effects in vivo [33]. 
However, clinical evidence of postprandial hypoglycemic effects of blackberries have 
not been studied.  
While cranberries and blackberries have shown the inhibitory effects on both yeast and 
rat ɑ-glucosidase enzyme activity, it is currently unclear whether cranberries and 
blackberries exert the inhibitory effects on ɑ-glucosidase activity in human Caco-2 
intestinal cells and whether the effects are related to total phenolic contents. Moreover, 
the underlying molecular mechanisms of individual berries on intestinal carbohydrate 
digestion and absorption are not well understood. The published studies evaluated 
potential efficacies of various berries without considering dietary factors such as 
sucrose and AS. Therefore, we evaluated antidiabetic effects by determining 
antioxidant capacity and total phenolic contents of berry extracts as well as rat and 
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Caco-2 ɑ-glucosidase activities. In addition, effects of berry extracts on gene expression 
of carbohydrate digesting enzymes and glucose transporters are evaluated in the 
presence of sucrose or AS as dietary strategies in the prevention and treatment of 
postprandial hyperglycemia and T2DM. 
 
3.3 Materials and methods 
Freeze-dried blackberry, strawberry, raspberry, blueberry, and cranberry powders were 
purchased from (North Bay Trading Co. (Brule, WI, USA). 2,2-Diphenyl-1-
picrylhydrezyl was purchased from Alfa Aesar. (Ward Hill, MA, USA). Folin-Ciocalteu 
phenol reagent, rat intestinal acetone powders, 4-nitrophenyl α-d-glucopyranoside 
reagents were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Sodium 
acetate, TPTZ (2,4,6-Tri(2-pyridyl)-s-triazine), Iron (III) chloride hexahydrate were 
purchased from Santa Cruz Biotechnology. (Dallas, TX, USA). 6-(N-(7-Nitrobenz-2-
oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (6-NBDG) was purchased from Cayman 
Chemical (Ann Arbor, MI). The fast SYBR real-time PCR master mix, Dulbecco’s 
modified Eagle’s medium (DMEM), fetal bovine serum (FBS), antibiotics, and trypsin-
EDTA were purchased from Life Technologies (Grand Island, NY, USA). The specific 
primers for quantitative real-time PCR were designed by Primer Quest program, and 
purchased from integrated DNA Technologies (Coralville, Iowa, USA). Unless noted 
otherwise, all chemicals were purchased from Fisher Scientific Company Co. 
(Bridgewater, NJ, USA). 
 
3.3.1 Sample preparations 
The extraction procedure was carried out according to the method of Michiels et al. 
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[121] with slight modifications. Freeze dried berry powders were extracted with solvent 
mixture (Acetone/water/acetic acid; 70:29.5:0.5 v/v) for 1 hr at room temperature in 
dark place by using multi vortexer at 1200 rpm. Berry extracts were then filtered with 
Whatman filter paper No.3. Remained acetone from sample extracts was removed and 
concentrated under reduced pressure at 35°C by using the rotary evaporator. The freeze-
dried powders were stored at – 80 ºC 
 
3.3.2 Cell culture 
Human intestinal Caco-2 cells (passage number 75-79) were seeded into cell culture 
plates and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were incubated at 
37°C in an atmosphere of 5% of CO2, and media was replaced every 48 hrs. The Caco-
2 cells were treated with samples at day 8 after confluence. In order to evaluate the 
effect of the berry extracts in presence of dietary sucrose or AS, cells were preincubated 
in DMEM without 10% of fetal bovine serum for 3 hrs prior to sample treatments. 
 
3.3.3 Total phenolic contents 
Total phenolic contents were determined following the procedure previously described 
by Blainsket al. [122] with a slight modification. 1 mL of sample was mixed with 10% 
(v/v) Folin-Ciocalteu phenol reagent and 2% Na2CO3 at the ratio of 1:1:1. The mixture 
was placed in dark place for 60 min and the observance was measured at 750 nm using 
Micro-Plate Reader (Molecular devices; Sunnyvale, CA, USA). The amounts of 
phenolic compounds were expressed as gallic acid equivalent (GAE μg/mL). Standard 
curve was obtained using various concentrations of gallic acid dissolved in water. 
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3.3.4 1,1-Diphenyl-2-Picrylhydrazyl (DPPH) radical scavenging activities 
The antioxidant capacity was determined by DPPH radical scavenging method as 
described by Tailor et al. [123] with some modifications. A sample solution (40 μL) was 
mixed with 160 μL of 400 mM DPPH solution in 95% ethanol. Then, the mixture was 
incubated for 10 min at room temperature. Absorbance was measured at 517 nm by a 
Micro-Plate Reader and compared with controls which contained 40 μL of 50% DMSO 
used to dissolve the extract powders. The DPPH radical scavenging activity was 
expressed as percent inhibition and calculated based on the formula as follows: 
Inhibition (%) =  �∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(517𝐴𝐴𝑛𝑛) −  ∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(517𝐴𝐴𝑛𝑛)
∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(517𝐴𝐴𝑛𝑛) � 𝐴𝐴 100 
 
 
3.3.5 Ferric reducing ability of plasma(FRAP) assay 
Ferric reducing ability of plasma was determined following the procedure previously 
described by Benzine et al. [124] with slight modification. FRAP reagent was made 
with 300 mM sodium acetate buffer (pH 3.6), 10 mM TPTZ (2,4,6-Tri(2-pyridyl)-s-
triazine) and 20 mM Iron (III) chloride hexahydrate with 10:1:1 ratio. TPTZ and Iron 
(III) chloride hexahydrate were dissolved in 40 mM hydrogen chloride before the 
experiment. 1.9 mL of FRAP reagent was mixed with in 100 ul of sample and incubated 
at room temperature for 30 min. The absorbance was measured at 593 nm by a Micro-
Plate Reader and compared with controls which contained 50% DMSO. Ferric reducing 
ability of plasma was expressed as ascorbic acid equivalent (AAE μM/mL). Standard 
curve was obtained using various concentrations of ascorbic acid.  
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3.3.6 Nitric oxide (NO) assay 
Nitric oxide was determined following the procedure previously described by Tsikas et 
al. [125] with slight modification. 1 mL of sodium nitrite (10 mM) was mixed with 1 
ml sample and pH was adjusted to 1.2 in the final volume of 10 mL. The mixture was 
then incubated at 37 °C for 1 h. After one hour, 0.4 ml of Griess reagent and 1 mL of 
mixture were mixed with 2.5 mL of 2% acetic acid. The mixture was then incubated for 
15 min until pigment was expressed. The absorbance was measured at 520 nm by a 
Micro-Plate Reader and compared with controls which contained 1 mL of 50% DMSO. 
The nitric oxide inhibitory activity was expressed as percent inhibition and calculated 
based on the formula as follows: 
Inhibition (%) =  �∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(520𝐴𝐴𝑛𝑛) −  ∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(520𝐴𝐴𝑛𝑛)
∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(520𝐴𝐴𝑛𝑛) � 𝐴𝐴 100 
 
 
3.3.7 Rat ɑ-glucosidase activity  
Rat intestinal α-glucosidase activity was determined using the substrate, 5 mM of p-
nitrophenyl-α-D-glucopyranoside (pNPG), as demonstrated by Kwon et al. [36] with a 
slight modification. Rat-intestinal acetone powder suspending in 0.9% of saline and 
vortexed for 6 min at 4 °C, centrifuging (13,000× g, 15 min, 4 °C), and supernatant was 
collected for the experiment. 100 μL of rat intestinal α-glucosidase solution (1.0 U/mL) 
was then mixed with 50 μL of sample solution and 50 μL of substrates or buffer, and 
was the mixture further incubated at 37 °C for 30 min. After incubation, Na2CO3 was 
added to stop the reaction. The absorbance was recorded at 405 nm by Micro-Plate 
Reader and compared with controls. The rat α-glucosidase inhibitory activity was 
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expressed as percent inhibition and calculated based on formulation as follows: 
Inhibition (%) =  �∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(405𝐴𝐴𝑛𝑛) −  ∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(405𝐴𝐴𝑛𝑛)
∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(405𝐴𝐴𝑛𝑛) � 𝐴𝐴 100 
 
 
3.3.8 Caco-2 ɑ-glucosidase activity  
Caco-2 ɑ-glucosidase activity was determined following the procedure previously 
described by Yu et al. [126]. Caco-2 cells were seeded into 6-well plates and collected 
with phosphate buffered saline (PBS) at 8 day after confluence. Caco-2 lysate (100 uL), 
sample solution (50 uL), and 5 mM pNPG solution or PBS were placed in 96-well plates. 
The mixture was then further incubated at 37 °C. After incubation, Na2CO3 was added 
to stop the reaction. The absorbance was measured at 405 nm using Micro-Plate Reader. 
The Caco-2 α-glucosidase inhibitory activity was expressed as percent inhibition and 
calculated same as ɑ-glucosidase activity. 
 
3.3.9 Caco-2 sucrase and glucoamylase activity  
Sucrase and glucoamylase activity were determined following the procedure previously 
described by Oh et al. [16] with a slight modification. Differentiated Caco-2 cells were 
harvested with PBS. The Caco-2 cell lysate was then mixed with 200 mM of sucrose 
for testing sucrase inhibitory activity or 1% of starch for testing glucoamylase 
inhibitory activity. Degree of enzymatic activity was determined by amount of glucose 
released from substrate in a given period of time by using Invitrogen glucose 
peroxidation kit from Invitrogen. The absorbance was measured at 560 nm by a Micro-
Plate Reader and compared with control. Caco-2 sucrase and glucoamylase activity 
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expressed as percent inhibition and calculated same as ɑ-glucosidase activity. 
 
3.3.10 qPCR 
The mRNA expression of Caco-2 cells was evaluated by RT-PCR. Total RNAs from 
differentiated Caco-2 cells were isolated by using TRIzol reagent by following the 
manufacture instruction. The RNA pellet was dissolved in RNase-free water, and RNA 
concentration and purity were measured by using nanodrop machine (Fisher, 
Bridgewater, NJ, USA) prior to cDNA synthesis. 1 μg of RNA was synthesized using 
RevertAid First Strand cDNA Synthesis kit (Thermo Scientific, Waltham, MA). 
Quantitative real time PCR reaction was performed with 100 ng of cDNA and 0.5 μM 
of forward and reverse primer with 2X Fast SYBR green Master Mix under 40 cycles. 
The expression level of each target gene is normalized to GAPDH and calculation was 
followed by delta delta ct calculation method (2ΔΔct). Primers for sodium glucose 
transporter 1 (SGLT1, forward (5’- GGG CAG CTT CAG GCA TC -3’) and reverse 
(5’- AAA CAG CCA GCC CAG CA -3’)) , glucose transporter 2 (GLUT2, forward (5’- 
ACG GCT GGT ATC AGC AAA C -3’) and reverse (5’- CTG CCT TCT CCA CAA 
GGA ATA C -3’)), glucose transporter 5 (GLUT5, forward (5’- GGC TGG GAC TCT 
GTG GA -3’) and reverse (5’- CAG CTT CAG CAC GGA GAT G -3’)), sucrose-
isomaltase (S-I, forward (5’- CCG GTG GCA TTC TGG ATT T -3’) and reverse (5’- 
TAT GCT GGC ATT GCT GGT AG -3’)), maltase-glucoamylase (M-G, forward (5’- 
TGC CTT CAC CAG TGT TT -3’) and reverse (5’- GGG CAC TTC AAA CCT GTT 
ATT G -3’)), TAS1R2 (T1R2, forward (5’- GCT GCC CAC CAA CTA CCA -3’) and 
reverse (5’- CGC TGT AGG CAG ACA TAG A -3’)), TAS1R3 (T1R3, forward (5’- 
CTG CTT TGG CCT GGT GTG -3’) and reverse (5’- GTG GGA CCA GGG CTG CT 
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-3’)), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, forward (5’- GAT 
GCT GGC GCT GAG TA -3’) and reverse (5’- GGC AGC GAT GAT GAC CCT TT -
3’)) were used. 
3.3.11 Glucose uptake 
Differentiated Caco-2 cells were pre-incubated with serum free DMEM for 3 hrs. 
Medium was then replaced with serum-free high glucose (25 mM) with or without a 
sample for 1 hour. After an hour, media was replaced with 6-NBDG for 15 mins. Cells 
lysate was prepared with lysis buffer (0.1M potassium phosphate buffer (pH10) 
containing 1% Trition X-100) and transferred into 96-well plate. The fluorescence was 
immediately measured using micro-plate reader (Excitation=460, emission=540). The 
rate of glucose uptake was normalized to control.  
 
3.3.12 Statistical Analysis 
All data were presented as the mean ± SD for each assay. Statistical analysis was carried 
out using SAS program (University edition SAS Inc. NC. USA) and significance of 
each group was verified with One-way analysis of variance (ANOVA) followed by the 
Duncan’s multiple range test and the Student’s t-test for comparison of means. p-values 
of less than 0.05 were considered to be statistically significant. 
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3.4 Results  
3.4.1 Total phenolic contents and antioxidant capacity of five berry extracts 
Total phenolic contents and antioxidant capacities of five different berries extracts, 
blackberry (BBE), cranberry (CBE), strawberry (SBE), raspberry (RBE), and blueberry 
(BLBE) extracts were evaluated to correlate the amount of phenolic contents with 
antioxidant capacity. As shown in Table 1, the amount of total phenolic contents among 
berry extracts varied from 28.55 ± 0.06 to 56.15 ± 1.08 gallic acid equivalent (GAE 
ug/mL). BBE showed the highest phenolic contents (28.55 ± 0.06 GAE ug/mL), 
whereas BLBE (28.55 ± 0.06 GAE ug/mL) showed the lowest total phenolic contents. 
In order to determine antioxidant capacity of five different berry extracts, three different 
antioxidant assays, ferric reducing ability power, DPPH radical, and nitric oxide 
scavenging activity were performed as shown in Table 1. Ferric reducing ability power 
(FRAP) of berry extracts calculated using ascorbic acid equivalent (AAE μM/mL). 
Among the five berries, BBE displayed the highest FRAP values (715 ± 20 AAE μM), 
and BLBE has the lowest FRAP values (287 ± 9 AAE μM). Antioxidant capacity of 
berry extracts against DPPH radicals (2,2-diphenyl-1-picrylhydrazyl) was quantified 
and half maximal inhibitory concentration (IC50) was measured. Within five berry 
extracts, BBE showed the lowest concentration IC50 (1.15 ± 0.01 mg/mL) which 
implicated the highest DPPH scavenging activities. In contrast, CBE and BLBE showed 
the lowest DPPH radical scavenging activities (IC50 > 2.5 mg/mL). Antioxidant 
capacities of berry extracts against nitric oxide (NO) was also quantified and IC50 values 
were measured. Similar to other antioxidant assays, BBE had the highest efficacy for 
scavenging nitric oxide (IC50: 2.46 ± 0.08 mg/mL), whereas CBE and BBE showed the 
lowest activity (IC50: > 5 mg/mL) for scavenging nitric oxide (Table 1). These results 
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indicate that antioxidant capacity is strongly correlated with total phenolic contents 
 
Total Phenolic Contents & Antioxidant Activities of Berry extracts 
Equivalent value of berry antioxidants 
 TPC FRAP DPPH NO 
 
GAE (μg/mL) AAE (μM/mL) IC50 (mg/mL) IC50 (mg/mL) 
BBE 56.15 ± 1.08a 715 ± 20a 1.15 ± 0.01 2.46 ± 0.08 
SBE 54.90 ± 1.23a 582 ± 16b 1.22± 0.08 2.98 ± 0.16 
RBE 34.65 ± 0.63b 450 ± 36c 1.95± 0.16 4.13± 0.03 
CBE 33.28 ± 0.57b 339 ± 26d > 2.5 > 5  
BLBE 28.55 ± 0.06c 287 ± 9e > 2.5 > 5 
 
Table 1. Total phenolic contents and antioxidant capacity of five different berries.  
Results were expressed as mean ± SD of three independent experiments in triplicate. 
Different corresponding letters indicate significant differences at p < 0.05 by Duncan’s 
test. TPC: total phenolic contents, FRAP: Ferric reducing ability of plasma, DPPH: 2.2-
diphenyl-1-picrylhydrazyl radical scavenging activity, NO: Nitric oxide inhibitory 
activity, GAE: Gallic acid equivalent, AAE: Ascorbic acid equivalent, BBE: Blackberry 
extracts, SBE: Strawberry extracts, RBE: Raspberry extracts, CBE: Cranberry extracts, 
BLBE: Blueberry extracts.  
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3.4.2 Effect of different berry extract on rat and Caco-2 ɑ-glucosidase activity  
The effects of different berry extracts on rat ɑ-glucosidase inhibitory activities was 
evaluated for screening antidiabetic potential of berry extracts, and 25 μM of Acarbose 
was included as a positive control. As shown in Figure 1 (A), all berry extracts dose 
dependently increased rat ɑ-glucosidase inhibitory activity. However, CBE and BBE 
showed the highest rat ɑ-glucosidase inhibitory activity by 74% and 72% respectively, 
while other berry extracts inhibited the rat ɑ-glucosidase activity by around 65% at 5 
mg/mL concentration.  
Many published studies have investigated antidiabetic effects of various berry extracts 
by determining yeast [28] and rat ɑ-glucosidase [29], which is often difficult to 
extrapolate the activity of data to humans. Therefore, effects of berry extracts on human 
ɑ-glucosidase activity was evaluated by using human Caco-2 intestinal cells. As shown 
in Figure 1 (B), effect of berry extracts on Caco-2 ɑ-glucosidase activity showed similar 
trends as rat ɑ-glucosidase activity (Data was not included 5 mg/mL concentration due 
to all extracts reached 100% inhibition). CBE showed the highest human Caco-2 ɑ-
glucosidase inhibitory activity (95%) at 2.5 mg/mL concentration, followed by black, 
and other three berry extracts. However, berry extracts showed higher inhibitory effects 
in human Caco-2 cells rather than rat ɑ-glucosidase.   
So far, the correlation between total phenolic contents and ɑ-glucosidase activity 
remains controversial, however, the amount of phenolic content are believed to 
correlate with ɑ-glucosidase inhibitory activities [127]. However, in our study, amount 
of total phenolic contents does not seem to correlate with ɑ-glucosidase activity. 
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Figure 1. Effects of five different berry extracts on rat and Caco-2 α-glucosidase 
activity. Rat and Caco-2 α-glucosidase activity were determined by measuring p-
nitrophenol released from pNPG at 405 nm. Results are expressed as mean ± SD of 
three independent experiments each performed in triplicates. Different corresponding 
letters indicate significant differences at p < 0.05 by Duncan’s test. AC: Acarbose, BBE: 
Blackberry extracts, SBE: Strawberry extracts, RBE: Raspberry extracts, CBE: 
Cranberry extracts, BLBE: Blueberry extracts.  
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3.4.3 Effects of CBE and BBE on sucrase and glucoamylase activity 
Among five different berries, we selected CBE and BBE based on the highest ɑ-
glucosidase inhibitory activity and total phenolic contents. However, in order to 
evaluate the ɑ-glucosidase inhibitory effects of berry extracts at physiological 
concentration, we evaluated effects of CBE and BBE on Caco-2 ɑ-glucosidase activity 
at low concentration (0 ~ 200 μg/mL). As shown in Figure 2, both CBE and BBE 
inhibited Caco-2 ɑ-glucosidase activities in dose dependent manner.  
ɑ-glucosidase is a cluster of several enzymes in the small intestine. Among the ɑ-
glucosidases, retardation of sucrase and glucoamylase activity are directly involved in 
postprandial hyperglycemia due to sucrose and starch are commonly consumed from 
our diet. Therefore, we evaluated effects of berry extracts on sucrase and glucoamylase 
activity. As shown in Figure 3, both CBE and BBE suppressed sucrase activities even 
at 50 μg/mL concentration and sucrase inhibitory activity were increased dose 
dependently. Although the both CBE and BBE showed inhibitory effects of 
glucoamlyase at 200 μg/mL concentration, only CBE seems to have glucoamylase 
inhibitory effects at 50 to 100 μg/mL concentrations (Figure 4). These data suggest that 
CBE and BBE have antidiabetic potentials by inhibiting sucrase and glucoamylase, but 
the efficacy of berry extracts on specific enzyme inhibitory effects may differ.  
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Figure 2. Effects of CBE and BBE on Caoc-2 ɑ-glucosidase activity. Caco-2 ɑ-
glucosidase activity was determined by measuring p-nitrophenol released from pNPG 
at 405 nm. Results are expressed as mean ± SD of three independent experiments each 
performed triplicate. Different corresponding letters indicate significant differences at 
p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry extracts. 
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Figure 3. Effects of CBE and BBE on Caco-2 sucrase activity. Sucrase inhibitory 
activity was determined by measuring glucose released from sucrose at 560 nm by using 
glucose peroxidation kit. Results are expressed as mean ± SD of three independent 
experiments each performed triplicate. Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: 
Blackberry extracts. 
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Figure 4. Effects of CBE and BBE on Caco-2 glucoamlyase activity. Glucoamlyase 
inhibitory activity was determined by measuring glucose released from starch at 560 
nm by using glucose peroxidation kit. Results are expressed as mean ± SD of three 
independent experiments each performed triplicate. Different corresponding letters 
indicate significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, 
BBE: Blackberry extracts 
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3.4.4 Effects of CBE and BBE on glucose uptake and gene expression in Caco-2 
cells 
Berry mixtures have been reported to suppress the glucose uptake by inhibiting glucose 
transporters [30], but individual berries were not examined. Individual berry extracts 
may have different molecular mechanisms to modify postprandial plasma glucose level. 
Hence, we investigated effects of CBE and BBE on glucose uptake as well as gene 
expression of glucose transporters and carbohydrate digesting enzymes in the small 
intestine.  
Physiological effects of CBE and BBE on enterocytes were determined by glucose 
uptake using 6-NBDG florescence probe. As shown in Figure 5, both CBE and BBE 
significantly decreased glucose uptake at 200 μg/mL concentration. However, only 
CBE reduced glucose uptake even at 100 μg/mL concentration.  
In order to identify molecular mechanisms of CBE and BBE, glucose transporters, 
SGLT1 and GLUT2, and two subunits of ɑ-glucosidase, S-I and M-G, were evaluated. 
As shown in Figure 6, both glucose transporters were significantly decreased in the 
presence of CBE at 200 μg/mL. Also, both carbohydrate digesting enzymes were 
significantly decreased at 200 μg/mL (Figure 7). On the other hand, BBE did not alter 
the both SGLT1 and GLUT2 mRNA expression, although BBE significantly reduced 
expression of S-I and M-G at 200 μg/mL concentration (Figure 10). These results 
suggest that CBE and BBE have different molecular mechanisms to prevent 
postprandial hyperglycemia.  
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Figure 5. Effects of CBE and BBE on glucose uptake in human Caco-2 intestinal 
cells. Human intestinal Caco-2 cells were treated with CBE or BBE extracts for 1hr. 
Glucose uptake was determined by measuring fluorescence of 6-NBDG in the cells. 
Excitation and emission wavelength for 6-NBDG is 465 nm and 540 nm respectively. 
Results are normalized to control group and presented as mean ± SD of three 
independent experiments (n=3). CBE: Cranberry extracts, BBE: Blackberry extracts. 
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Figure 6. Effects of CBE on glucose transporter expression. Human intestinal Caco-
2 cells were treated with different concentrations of CBE (0~200 μg/mL) for 1hr. 
SGLT1 and GLUT2 mRNA level were normalized to GAPDH as housekeeping genes. 
Results are presented relative value compare to the control groups as mean ± SD of 
three independent experiments (n=3). Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts. 
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Figure 7. Effects of CBE on carbohydrate digesting enzyme expression. Human 
intestinal Caco-2 cells were treated with different concentrations of CBE (0~200 μg/mL) 
for 1hr. S-I and M-G mRNA levels were normalized to GAPDH as housekeeping genes. 
Results are presented relative value compare to the control groups as mean ± SD of 
three independent experiments (n=3). Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts. 
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Figure 8. Effects of BBE on glucose transporter expression. Human intestinal Caco-
2 cells were treated with different concentrations of BBE (0~200 μg/mL) for 1hr. 
SGLT1 and GLUT2 mRNA levels were normalized to GAPDH as housekeeping genes. 
Results are presented relative value compare to the control groups as mean ± SD of 
three independent experiments (n=3). Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test. BBE: Blackberry extracts. 
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Figure 9. Effects of BBE on carbohydrate digesting enzyme expression. Human 
intestinal Caco-2 cells were treated with different concentrations of BBE (0~200 μg/mL) 
for 1hr. S-I and M-G mRNA level were normalized to GAPDH as housekeeping genes. 
Results are presented relative value compare to the control groups as mean ± SD of 
three independent experiments (n=3). Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test. BBE: Blackberry extracts. 
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3.4.5 Effects of sucrose on small intestinal ɑ-glucosidase, glucose transporters, 
and glucose uptake in Caco-2 cells 
Dietary sucrose has been considered as a major determinant of postprandial 
hyperglycemia. However, effects of sucrose on small intestinal ɑ-glucosidase and 
glucose transporters were not well understood in in vitro stetting. Therefore, we selected 
the concentrations ranging from 25 mM to 100 mM of sucrose to determine the effects 
of sucrose on intestinal digestion and absorption in the small intestine.   
In order to determine physiological effects of sucrose on enterocytes, glucose uptake 
was performed by using 6-NDBG probe. As shown in Figure 10, there were no changes 
until 100 mM of sucrose. When the cells are exposed to 100 mM of sucrose, glucose 
uptake was significantly increased by 30%   
Sucrose is hydrolyzed into glucose and fructose, which are then transported by glucose 
transporters (SGLT1, GLUT2) and fructose transporter (GLUT2, GLUT5) into 
enterocytes. As shown in Figure 11, mRNA expression of SGLT1, GLUT2, and GLUT5 
was not changed in the presence of 50 mM of sucrose. However, mRNA expression of 
these glucose transporters was significantly elevated by around 20~30% at 100 mM of 
sucrose compare to control  
From Between two subunits of ɑ-glucosidase, only sucrose hydrolyzing enzyme, S-I, 
was significantly increased in presence of 100 mM sucrose, whereas starch hydrolyzing 
enzyme, M-G, was not altered in the presence of 100 mM of sucrose (Figure 12). 
Therefore, 100 mM sucrose were further tested for evaluating effects of CBE and BBE 
in presence of dietary sucrose. 
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Figure 10. Effects of sucrose on glucose uptake. Human intestinal Caco-2 cells were 
treated with different concentration of sucrose for 1hr. Glucose uptake was determined 
by measuring fluorescence of 6-NBDG in the cells. Excitation and emission wavelength 
for 6-NBDG is 465 nm and 540 nm respectively. Results are normalized to control 
group and presented as mean ± SD of three independent experiments (n=3).  
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Figure 11. Effects of sucrose on glucose transporter expression. Human intestinal 
Caco-2 cells were treated with different concentrations of sucrose (25~100 mM) for 1hr. 
SGLT1, GLUT2, and GLUT5 mRNA levels were normalized to GAPDH as 
housekeeping genes. Results are presented relative value compare to the control groups 
as mean ± SD of three independent experiments (n=3). Different corresponding letters 
indicate significant differences at p < 0.05 by Duncan’s test.  
 
46 
m
R
N
A 
ex
pr
es
si
on
0.0
0.5
1.0
1.5
2.0
Control
25 mM
50 mM
100 mM
a a
ab
a
a a a a
S-I M-G
 
Figure 12. Effects of sucrose on carbohydrate digesting enzyme expression. Human 
intestinal Caco-2 cells were treated with different concentrations of sucrose (25 ~ 100 
mM) for 1hr. S-I and M-G mRNA levels were normalized to GAPDH as housekeeping 
genes. Results are presented relative value compare to the control groups as mean ± SD 
of three independent experiments (n=3). Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test.  
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3.4.6 Effects of CBE and BBE on small intestinal ɑ-glucosidase, glucose 
transporters, and glucose uptake in Caco-2 cells  
Next, we investigated the effects of CBE and BBE on intestinal ɑ-glucosidase, glucose 
transporters as well as glucose uptake in the presence of sucrose. Physiological effects 
of CBE and BBE on human intestinal cells were determined by glucose uptake (Figure 
13). In the presence of 100 mM of sucrose, glucose uptake was significantly increased, 
which was markedly decreased in the presence of CBE or BBE.  
Effect of CBE and BBE on glucose transporters and ɑ-glucosidase enzymes in the 
presence of sucrose were determined. As shown in Figure 14, mRNA levels of SGLT1, 
GLUT2, and GLUT5 were significance increased by 100 mM sucrose, which was 
significantly attenuated in presence of CBE and BBE. Furthermore, S-I was elevated in 
the presence of 100 mM of sucrose and was diminished in the presence of CBE or BBE. 
In the case of the M-G, it was not altered in the presence of dietary sucrose but it was 
downregulated by the CBE or BBE (Figure 15). These results suggest that CBE and 
BBE may regulate postprandial hyperglycemia in high sucrose diet by modifying 
glucose transporters as well as carbohydrate digesting enzymes.  
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Figure 13. Effects of CBE and BBE on glucose uptake in the presence of sucrose. 
Human intestinal Caco-2 intestinal cells were treated with 200 μg/mL of CBE or BBE 
extracts in the presence of 100 mM of sucrose for 1hr. Glucose uptake was determined 
by measuring fluorescence of 6-NBDG in the cells. Excitation and emission wavelength 
for 6-NBDG is 465 nm and 540 nm respectively. Results are normalized to control 
group and presented as mean ± SD of three independent experiments (n=3). CBE: 
Cranberry extracts, BBE: Blackberry extracts 
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Figure 14. Effects of CBE and BBE on glucose transporter expression in the 
presence of sucrose. Human intestinal Caco-2 intestinal cells were treated with 200 
μg/mL of CBE or BBE in the presence of sucrose (100 mM) for 1hr. SGLT1, GLUT2, 
and GLUT5 mRNA levels were normalized to GAPDH as housekeeping genes. Results 
are presented relative value compare to the control groups as mean ± SD of three 
independent experiments (n=3). Different corresponding letters indicate significant 
differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry 
extracts. CBE: Cranberry extracts, BBE: Blackberry extracts 
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Figure 15. Effects of sucrose on carbohydrate digesting enzyme expression in the 
presence of sucrose. Human intestinal Caco-2 intestinal cells were treated with 200 
μg/mL of CBE or BBE in the presence of sucrose (100 mM) for 1hr. S-I and M-G 
mRNA levels were normalized to GAPDH as housekeeping genes. Results are 
presented relative value compare to the control groups as mean ± SD of three 
independent experiments (n=3). Different corresponding letters indicate significant 
differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry 
extracts. CBE: Cranberry extracts, BBE: Blackberry extracts 
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3.4.7 Effects of sucralose on small intestinal ɑ-glucosidase, glucose transporters, 
sweet-sensing receptors and glucose uptake in Caco-2 cells  
Sucralose is one of artificial sweeteners that have been extensively used in various food 
products and beverages as an alternative to dietary sucrose [9]. Although sucralose is 
non-digestible and non-absorbable, there is evidence showing that dietary AS increased 
intestinal glucose transporters [12]. However, effects of sucralose on intestinal 
digestion and absorption are not currently known. Hence, the effect of sucralose was 
evaluated with different concentrations selected based on daily accepted intake of 
sucralose from FDA.  
Glucose uptake was evaluated to identify physiological effects of sucralose on glucose 
absorption in enterocytes. As shown in Figure 16, glucose uptake was not increased in 
the presence of 1 mM sucralose but it was significantly elevated at 10 mM of sucralose 
compared to control.  
As shown in Figure 17, 10 mM of sucralose significantly elevated SGLT1 and GLUT2 
expression significantly without altering GLUT5. Effects of sucralose on ɑ-glucosidase 
activity and its mRNA expressions were evaluated. Unlike sucrose, both ɑ-glucosidase 
activity and gene expression of S-I and M-G, was not altered in the presence of 
sucralose (Figure 18). Expression of both sweet sensing receptors, T1R2 and T1R3 in 
Caco-2 cells were also evaluated and were increased dose dependently (Figure 19). 
Although molecular mechanisms between sweet-sensing receptors and SGLT1 are yet 
to be identified, the expression of T1R2 and T1R3 mRNA was similarly increasing as 
SGLT1 by sucralose treatment.  
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Figure 16. Effects of sucralose on glucose uptake human Caco-2 intestinal cells were 
treated with different concentration of sucralose for 1hr. Glucose uptake was 
determined by measuring fluorescence of 6-NBDG in the cells. Excitation and emission 
wavelength for 6-NBDG is 465 nm and 540 nm respectively. Results are normalized to 
control group and presented as mean ± SD of three independent experiments (n=3). 
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Figure 17. Effects of sucralose on glucose transporter expression. human Caco-2 
intestinal cells were treated with different concentrations of sucralose (1, 10 mM) for 
1hr. SGLT1, GLUT2, and GLUT5 mRNA levels were normalized to GAPDH as 
housekeeping genes. Results are presented relative value compare to the control groups 
as mean ± SD of three independent experiments (n=3). Different corresponding letters 
indicate significant differences at p < 0.05 by Duncan’s test.  
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Figure 18. Effects of sucralose on carbohydrate digesting enzyme expression. 
Caco-2 cells were treated with different concentrations of sucralose (1, 10 mM) for 1hr. 
S-I and M-G mRNA levels were normalized to GAPDH as housekeeping genes. Results 
are presented relative value compare to the control groups as mean ± SD with three 
independent experiments (n=3). Different corresponding letters indicate significant 
differences at p < 0.05 by Duncan’s test.  
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Figure 19. Effects of sucralose on sweet-sensing receptors expression. human Caco-
2 intestinal cells were treated with different concentrations of sucralose (1, 10 mM) for 
1hr. T1R2 and T1R3 mRNA levels were normalized to GAPDH as housekeeping genes. 
Results are presented relative value compare to the control groups as mean ± SD of 
three independent experiments (n=3). Different corresponding letters indicate 
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: 
Blackberry extracts. 
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3.4.8 Effects of CBE and BBE on small intestinal ɑ-glucosidase, glucose 
transporters, sweet-sensing receptors and glucose uptake in the presence of 
sucralose in Caco-2 cells  
To determine physiological effects CBE or BBE on enterocytes in the presence of 10 
mM of sucralose, glucose uptake was performed (Figure 20). Compared to control, 10 
mM sucralose elevated glucose uptake by 10%, but suppressed in the presence of 200 
μg/mL of CBE or BBE.  
Next, we evaluated the molecular mechanisms of CBE and BBE on intestinal digestive 
enzymes and sweet-sensing receptors in the presence of 10 mM of sucralose. As shown 
in Figure 22, BBE suppressed all glucose transporters, SGLT1, GLUT2, and GLUT5, 
whereas CBE only suppressed GLUT2 and GLUT 5 without effect on the SGLT1 
expression in presence of 10 mM of sucralose. Furthermore, sweet-sensing receptors, 
T1R2 and T1R3, were elevated in presence of sucralose and were attenuated in the 
presence of 200 μg/mL of CBE or BBE (Figure 23). Moreover, between CBE and BBE, 
BBE had higher inhibitory effects on the T1R2 expression than CBE. As shown in 
previous results, sucralose did not affect the expression of carbohydrate- digesting 
enzymes. However, CBE and BBE suppressed S-I, and M-G mRNA expression (Figure 
22).  
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Figure 20. Effects of CBE and BBE on glucose uptake in the presence of sucralose. 
Human intestinal Caco-2 cells were treated with 200 μg/mL of CBE or BBE extracts in 
presence of 10 mM of sucralose for 1hr. Glucose uptake was determined by measuring 
fluorescence of 6-NBDG in the cells. Excitation and emission wavelength for 6-NBDG 
is 465 nm and 540 nm respectively. Results are normalized to control group and 
presented as mean ± SD of three independent experiments (n=3). CBE: Cranberry 
extracts, BBE: Blackberry extracts. 
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Figure 21. Effects of CBE and BBE on glucose transporter expression in the 
presence of sucralose Human intestinal Caco-2were treated with 200 μg/mL of CBE 
or BBE in presence of sucralose (10 mM) for 1hr. SGLT1, GLUT2, and GLUT5 mRNA 
levels were normalized to GAPDH as housekeeping genes. Results are presented 
relative value compare to the control groups as mean ± SD of three independent 
experiments (n=3). Different corresponding letters indicate significant differences at p 
< 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry extracts. 
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Figure 22. Effects of sucrose on carbohydrate digesting enzyme expression in the 
presence of sucralose. Human intestinal Caco-2 were treated with 200 μg/mL of CBE 
or BBE in presence of sucralose (10 mM) for 1hr. S-I and M-G mRNA levels were 
normalized to GAPDH as housekeeping genes. Results are presented relative value 
compare to the control groups as mean ± SD of three independent experiments (n=3). 
Different corresponding letters indicate significant differences at p < 0.05 by Duncan’s 
test. CBE: Cranberry extracts, BBE: Blackberry extracts. CBE: Cranberry extracts, 
BBE: Blackberry extracts. 
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Figure 23. Effects of sucrose on sweet-sensing receptors expression in the presence 
of sucralose. Human intestinal Caco-2 were treated with 200 μg/mL of CBE or BBE in 
presence of sucralose (10 mM) for 1hr. T1R2 and T1R3 mRNA levels were normalized 
to GAPDH as housekeeping genes. Results are presented relative value compare to the 
control groups as mean ± SD of three independent experiments (n=3). Different 
corresponding letters indicate significant differences at p < 0.05 by Duncan’s test. CBE: 
Cranberry extracts, BBE: Blackberry extracts. 
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3.4.9 Conclusion 
In the current study, cranberry and blackberry extracts were evaluated for potential 
benefits against postprandial hyperglycemia, a key metabolic feature of T2DM and its 
complication. Our finding showed significant evidence of CBE and BBE in lowering 
plasma levels after a meal. In particular, we found that both CBE and BBE reduced 
glucose uptake in the presence of sucrose and sucralose in human intestinal Caco-2 cell 
line. The ability of CBE and BBE to prevent sucrose and sucralose-induced intestinal 
glucose uptake is associated with inhibition of ɑ-glucosidase activity as well as gene 
expression. Notably, BBE with higher total phenolic contents than CBE showed ɑ-
glucosidase inhibitory activity with no effects on glucose transporters, while CBE 
showed inhibitory actions on both. These results show that certain berries exhibit more 
potential for the prevention of postprandial hyperglycemia than others, indicating that 
specific profile of nutrients and/or phenolic compounds present in different berries is 
of importance for the observed cellular effects. 
Current findings also suggest the involvement of sweet-sensing receptors as potential 
upstream targets that regulate glucose transport and uptake. Taken together, our results 
suggest that increased intake of berries may be a promising strategy to delay 
postprandial glucose flux into the system and has important implications in the 
prevention of T2DM & its complications. However, the potential benefits of berry 
extracts need to be verified in in vivo and clinical studies in order to confirm the 
physiological relevance of current findings. 
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